JP2014516518A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014516518A5 JP2014516518A5 JP2014508476A JP2014508476A JP2014516518A5 JP 2014516518 A5 JP2014516518 A5 JP 2014516518A5 JP 2014508476 A JP2014508476 A JP 2014508476A JP 2014508476 A JP2014508476 A JP 2014508476A JP 2014516518 A5 JP2014516518 A5 JP 2014516518A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- sequence
- mouse
- immunoglobulin
- rearranged
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 claims description 38
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 24
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 24
- 210000004602 germ cell Anatomy 0.000 claims description 20
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 19
- 108060003951 Immunoglobulin Proteins 0.000 claims description 18
- 102000018358 immunoglobulin Human genes 0.000 claims description 18
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 16
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 16
- 238000000034 method Methods 0.000 claims 9
- 230000000392 somatic effect Effects 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 28
- 241000699670 Mus sp. Species 0.000 description 6
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102100029567 Immunoglobulin kappa light chain Human genes 0.000 description 1
- 101710189008 Immunoglobulin kappa light chain Proteins 0.000 description 1
- 101000840255 Mus musculus Immunoglobulin kappa constant Proteins 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/093,156 | 2011-04-25 | ||
| US13/093,156 US20120021409A1 (en) | 2010-02-08 | 2011-04-25 | Common Light Chain Mouse |
| PCT/US2012/034737 WO2012148873A2 (en) | 2011-04-25 | 2012-04-24 | Non-human animals expressing antibodies having a common light chain |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016138445A Division JP6522557B2 (ja) | 2011-04-25 | 2016-07-13 | 共通の軽鎖を有する抗体を発現する非ヒト動物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014516518A JP2014516518A (ja) | 2014-07-17 |
| JP2014516518A5 true JP2014516518A5 (enExample) | 2016-04-07 |
| JP6393613B2 JP6393613B2 (ja) | 2018-09-19 |
Family
ID=46000410
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014508476A Active JP6393613B2 (ja) | 2011-04-25 | 2012-04-24 | 共通の軽鎖を有する抗体を発現する非ヒト動物 |
| JP2016138445A Active JP6522557B2 (ja) | 2011-04-25 | 2016-07-13 | 共通の軽鎖を有する抗体を発現する非ヒト動物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016138445A Active JP6522557B2 (ja) | 2011-04-25 | 2016-07-13 | 共通の軽鎖を有する抗体を発現する非ヒト動物 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20120021409A1 (enExample) |
| EP (2) | EP2701499B2 (enExample) |
| JP (2) | JP6393613B2 (enExample) |
| KR (1) | KR101995753B1 (enExample) |
| CN (2) | CN105884887A (enExample) |
| AU (3) | AU2012249953B2 (enExample) |
| BR (1) | BR112013027420A2 (enExample) |
| CA (1) | CA2846806A1 (enExample) |
| CY (2) | CY1117606T1 (enExample) |
| DK (2) | DK2701499T4 (enExample) |
| ES (2) | ES2573828T5 (enExample) |
| HR (2) | HRP20160484T4 (enExample) |
| HU (2) | HUE045401T2 (enExample) |
| IL (1) | IL228929A0 (enExample) |
| LT (1) | LT2989893T (enExample) |
| MX (1) | MX353609B (enExample) |
| PL (2) | PL2989893T3 (enExample) |
| PT (1) | PT2989893T (enExample) |
| RS (2) | RS59331B1 (enExample) |
| RU (2) | RU2614859C2 (enExample) |
| SG (1) | SG194466A1 (enExample) |
| SI (2) | SI2701499T2 (enExample) |
| SM (2) | SMT201900514T1 (enExample) |
| WO (1) | WO2012148873A2 (enExample) |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
| DK2314629T4 (da) | 2002-07-18 | 2023-02-06 | Merus Nv | Rekombinant produktion af blandinger af antistoffer |
| US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| WO2004106375A1 (en) | 2003-05-30 | 2004-12-09 | Merus Biopharmaceuticals B.V. I.O. | Fab library for the preparation of anti vegf and anti rabies virus fabs |
| CN104761637B (zh) | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| ES2595638T3 (es) | 2007-09-26 | 2017-01-02 | Chugai Seiyaku Kabushiki Kaisha | Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
| DK3622815T3 (da) | 2009-07-08 | 2023-06-26 | Kymab Ltd | Gnavermodeller og terapeutiske molekyler |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| SMT202600080T1 (it) | 2010-02-08 | 2026-03-09 | Regeneron Pharma | Topo con catena leggera comune |
| SMT201700023T1 (it) | 2010-08-02 | 2017-03-08 | Regeneron Pharma | Topi che producono proteine leganti vl |
| PT3434767T (pt) | 2010-11-30 | 2026-01-23 | Chugai Pharmaceutical Co Ltd | Agente terapêutico indutor de citotoxicidade |
| ME02106B (me) | 2011-02-25 | 2015-10-20 | Regeneron Pharma | Miševi sa adam6 |
| AR085404A1 (es) | 2011-02-28 | 2013-09-25 | Hoffmann La Roche | Proteinas de union a antigeno |
| MX342034B (es) | 2011-02-28 | 2016-09-12 | Hoffmann La Roche | Proteinas monovalentes que se unen a antigenos. |
| HUE047278T2 (hu) | 2011-08-05 | 2020-04-28 | Regeneron Pharma | Humanizált univerzális könnyûláncú egerek |
| BR112014006394A2 (pt) | 2011-09-19 | 2017-03-28 | Kymab Ltd | manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos |
| WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
| CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
| SG11201401181YA (en) | 2011-10-17 | 2014-04-28 | Regeneron Pharma | Restricted immunoglobulin heavy chain mice |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| SG10201605675WA (en) | 2011-12-20 | 2016-09-29 | Regeneron Pharma | Humanized light chain mice |
| EP3539374A1 (en) | 2012-03-16 | 2019-09-18 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing ph-sensitive immunoglobulin sequences |
| WO2013138681A1 (en) | 2012-03-16 | 2013-09-19 | Regeneron Pharmaceuticals, Inc. | Mice that produce antigen-binding proteins with ph-dependent binding characteristics |
| US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
| EP2825036B1 (en) | 2012-03-16 | 2018-05-02 | Regeneron Pharmaceuticals, Inc. | Histidine engineered light chain antibodies and genetically modified rodents for generating the same |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| US9248181B2 (en) | 2012-04-20 | 2016-02-02 | Merus B.V. | Methods and means for the production of Ig-like molecules |
| ME03551B (me) * | 2012-06-12 | 2020-07-20 | Regeneron Pharma | Humanizovane nehumane živoтinje sa ograničenim lokusima imunoglobulinskog тeškog lanca |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| MY178882A (en) | 2013-02-20 | 2020-10-21 | Regeneron Pharma | Non-human animals with modified immunoglobulin heavy chain sequences |
| EP4545567A3 (en) * | 2013-03-13 | 2025-08-13 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| HK1218550A1 (zh) * | 2013-03-13 | 2017-02-24 | Regeneron Pharmaceuticals, Inc. | 常見輕鏈小鼠 |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| KR102049990B1 (ko) | 2013-03-28 | 2019-12-03 | 삼성전자주식회사 | c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질 |
| US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| RU2019121863A (ru) * | 2013-09-18 | 2019-08-29 | Регенерон Фармасьютикалз, Инк. | Антитела со встроенным в легкие цепи гистидином и генетически модифицированные отличные от человека животные для их получения |
| AU2014330922A1 (en) | 2013-10-01 | 2016-03-03 | Kymab Limited | Animal models and therapeutic molecules |
| BR112016006929A2 (pt) | 2013-10-11 | 2017-09-19 | Hoffmann La Roche | Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo |
| AU2015231025A1 (en) | 2014-03-21 | 2016-09-15 | Regeneron Pharmaceuticals, Inc. | Vl antigen binding proteins exhibiting distinct binding characteristics |
| CA3124228C (en) * | 2014-03-21 | 2024-05-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
| PE20170441A1 (es) | 2014-06-06 | 2017-04-26 | Bristol Myers Squibb Co | Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos |
| MA40764A (fr) * | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| JP2017531642A (ja) | 2014-10-03 | 2017-10-26 | マサチューセッツ インスティテュート オブ テクノロジー | エボラ糖タンパク質に結合する抗体およびその使用 |
| AU2015349878A1 (en) | 2014-11-21 | 2017-05-25 | Bristol-Myers Squibb Company | Antibodies against CD73 and uses thereof |
| WO2016097865A1 (en) | 2014-12-19 | 2016-06-23 | Regenesance B.V. | Antibodies that bind human c6 and uses thereof |
| JP6180663B2 (ja) | 2014-12-23 | 2017-08-16 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｉｇｉｔに対する抗体 |
| CA2979702A1 (en) * | 2015-03-19 | 2016-09-22 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
| JP7082484B2 (ja) | 2015-04-01 | 2022-06-08 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| DK3303396T5 (da) | 2015-05-29 | 2024-10-07 | Bristol Myers Squibb Co | Antistoffer mod ox40 og anvendelser deraf |
| CN107922500A (zh) | 2015-06-29 | 2018-04-17 | 洛克菲勒大学 | 具有增强的激动剂活性的抗cd40抗体 |
| TW201713690A (zh) * | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| WO2017035274A1 (en) * | 2015-08-27 | 2017-03-02 | Crystal Bioscience Inc. | Transgenic animal for production of antibodies having a common light chain |
| TW202417497A (zh) | 2015-10-12 | 2024-05-01 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| AU2016356780A1 (en) | 2015-11-19 | 2018-06-28 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof |
| KR20230006929A (ko) | 2016-01-13 | 2023-01-11 | 리제너론 파마슈티칼스 인코포레이티드 | 조작된 중쇄 다양성 영역을 갖는 설치류 |
| ES2985566T3 (es) | 2016-03-04 | 2024-11-06 | Univ Rockefeller | Anticuerpos contra CD40 con actividad agonista mejorada |
| EP3423494A1 (en) | 2016-03-04 | 2019-01-09 | Bristol-Myers Squibb Company | Combination therapy with anti-cd73 antibodies |
| US11072666B2 (en) | 2016-03-14 | 2021-07-27 | Chugai Seiyaku Kabushiki Kaisha | Cell injury inducing therapeutic drug for use in cancer therapy |
| MX392069B (es) | 2016-05-09 | 2025-03-21 | Bristol Myers Squibb Co | Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos. |
| CN113831407B (zh) | 2016-05-20 | 2024-06-11 | 瑞泽恩制药公司 | 用于使用多个引导rna来破坏免疫耐受性的方法 |
| KR102483193B1 (ko) | 2016-06-03 | 2023-01-04 | 리제너론 파마슈티칼스 인코포레이티드 | 외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물 |
| CN109757103B (zh) | 2016-07-14 | 2024-01-02 | 百时美施贵宝公司 | 针对tim3的抗体及其用途 |
| US10981976B2 (en) | 2016-08-31 | 2021-04-20 | University Of Rochester | Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof |
| MX2019004371A (es) | 2016-10-13 | 2019-11-18 | Massachusetts Inst Technology | Anticuerpos que se unen a la proteina de envoltura del virus zika y usos de los mismos. |
| CA3051839A1 (en) | 2017-02-17 | 2018-08-23 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
| TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| GB201710984D0 (en) * | 2017-07-07 | 2017-08-23 | Kymab Ltd | Cells, vertebrates, populations & methods |
| WO2019126194A1 (en) | 2017-12-18 | 2019-06-27 | Regeneron Pharmaceuticals, Inc. | Angptl8 assay and uses thereof |
| EP3737700A1 (en) | 2018-01-12 | 2020-11-18 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
| EP3768715A1 (en) | 2018-03-23 | 2021-01-27 | Bristol-Myers Squibb Company | Antibodies against mica and/or micb and uses thereof |
| EP3772927B1 (en) | 2018-03-24 | 2025-01-15 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice or rats for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof |
| PT3773713T (pt) | 2018-04-06 | 2025-07-29 | Regeneron Pharma | Anticorpo agonista do recetor de leptina para usar no aumento da massa óssea num sujeito que sofre de disfunção metabólica ou de hipoleptinemia |
| IL318469A (en) | 2018-06-14 | 2025-03-01 | Regeneron Pharma | Non-human animals capable of reorganizing transgenic DH-DH, and their uses |
| CN113316590B (zh) | 2018-11-16 | 2025-02-28 | 百时美施贵宝公司 | 抗nkg2a抗体及其用途 |
| CN113396162B (zh) | 2019-01-22 | 2024-08-16 | 百时美施贵宝公司 | 抗IL-7Rα亚基的抗体及其用途 |
| BR112021016173A2 (pt) | 2019-02-22 | 2021-11-03 | Regeneron Pharma | Roedor geneticamente modificado, métodos de produção de um roedor geneticamente modificado e de produção de um anticorpo anti-nav1.7, célula ou tecido isolado de roedor, linhagem celular imortalizada, embrião de roedor, construto de ácido nucleico de direcionamento, e, hibridoma |
| BR112022002067A2 (pt) | 2019-08-08 | 2022-06-14 | Regeneron Pharma | Formatos de molécula de ligação ao antígeno |
| US20220409732A1 (en) | 2019-12-02 | 2022-12-29 | Regeneron Pharmaceuticals, Inc. | Peptide-mhc ii protein constructs and uses thereof |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| US20230192867A1 (en) | 2020-05-15 | 2023-06-22 | Bristol-Myers Squibb Company | Antibodies to garp |
| US20220090060A1 (en) | 2020-09-11 | 2022-03-24 | Regeneron Pharmaceuticals, Inc. | Identification and production of antigen-specific antibodies |
| CN116848254B (zh) | 2020-12-16 | 2026-03-17 | 瑞泽恩制药公司 | 表达人源化Fcα受体的小鼠 |
| CA3165366A1 (en) | 2020-12-23 | 2022-06-30 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding anchor modified antibodies and uses thereof |
| IL303865A (en) | 2020-12-23 | 2023-08-01 | Regeneron Pharma | Methods for obtaining antibodies that bind transmembrane proteins and cells that produce them |
| TW202430641A (zh) * | 2023-01-18 | 2024-08-01 | 美商基利科學股份有限公司 | 人類免疫球蛋白二元輕鏈轉殖基因構築體及其用途 |
| EP4658687A1 (en) | 2023-01-31 | 2025-12-10 | University of Rochester | Immune checkpoint blockade therapy for treating staphylococcus aureus infections |
| WO2025184208A1 (en) | 2024-02-27 | 2025-09-04 | Bristol-Myers Squibb Company | Anti-ceacam5 antibodies and uses thereof |
| WO2026019824A1 (en) * | 2024-07-16 | 2026-01-22 | Gilead Sciences, Inc. | Human immunoglobulin common light chain transgene constructs and uses thereof |
| WO2026030428A2 (en) | 2024-08-01 | 2026-02-05 | Regeneron Pharmaceuticals, Inc. | Prostate-specific antigen peptides and uses thereof |
| WO2026035843A2 (en) | 2024-08-06 | 2026-02-12 | Regeneron Pharmaceuticals, Inc. | Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| ATE158021T1 (de) * | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US7041871B1 (en) * | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5770429A (en) * | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| IL109168A0 (en) * | 1993-04-01 | 1994-06-24 | Univ Columbia | A retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and making cells resistant to the chemotherapeutic agent cyclophosphamide and its derivatives and analogs |
| BRPI9809391B8 (pt) * | 1997-04-14 | 2021-05-25 | Amgen Res Munich Gmbh | processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica |
| ATE299938T1 (de) * | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| US6774279B2 (en) | 1997-05-30 | 2004-08-10 | Carnegie Institution Of Washington | Use of FLP recombinase in mice |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| MXPA05000511A (es) * | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| PT1652920E (pt) * | 2001-10-01 | 2010-11-08 | Deutsches Krebsforsch | Processo para a produção de bibliotecas de proteínas e para a selecção de proteínas a partir da mesma |
| EP2319301B1 (en) * | 2001-11-30 | 2017-09-06 | Amgen Fremont Inc. | Transgenic animals bearing human Ig lambda light chain genes |
| WO2003061363A2 (en) * | 2002-01-17 | 2003-07-31 | Albert Einstein College Of Medicine Of Yeshiva University | Mutations caused by activation-induced cytidine deaminase |
| ES2524767T3 (es) * | 2002-06-14 | 2014-12-12 | Immunomedics, Inc. | Anticuerpo monoclonal humanizado HPAM4 |
| DK2314629T4 (da) * | 2002-07-18 | 2023-02-06 | Merus Nv | Rekombinant produktion af blandinger af antistoffer |
| WO2004106375A1 (en) | 2003-05-30 | 2004-12-09 | Merus Biopharmaceuticals B.V. I.O. | Fab library for the preparation of anti vegf and anti rabies virus fabs |
| US20100069614A1 (en) * | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| CN1560081A (zh) * | 2004-02-17 | 2005-01-05 | 大连帝恩生物工程有限公司 | 用能产生人IgGl重链－κ轻链小鼠作为制备人源化单克隆抗体和应用 |
| ES2463476T3 (es) | 2004-10-19 | 2014-05-28 | Regeneron Pharmaceuticals, Inc. | Método para generar un ratón homocigótico para una modificación genética |
| US7850965B2 (en) * | 2005-12-05 | 2010-12-14 | Symphogen A/S | Anti-orthopoxvirus recombinant polyclonal antibody |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| EP2583551A1 (en) * | 2007-03-13 | 2013-04-24 | National Jewish Health | Methods for generation of antibodies |
| ITMI20071522A1 (it) * | 2007-07-27 | 2009-01-28 | Areta Internat S R L | Vaccino idiotipico |
| EP2147594B1 (en) * | 2008-06-27 | 2013-11-13 | Merus B.V. | Antibody producing non-human mammals |
| CA2742969A1 (en) * | 2008-11-07 | 2010-05-14 | Fabrus Llc | Anti-dll4 antibodies and uses thereof |
| CA2758356C (en) * | 2009-05-29 | 2016-07-26 | Morphosys Ag | A collection of vh and vl pairs having favourable biophysical properties and methods for its use |
| MY192182A (en) * | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| SMT202600080T1 (it) | 2010-02-08 | 2026-03-09 | Regeneron Pharma | Topo con catena leggera comune |
| MX2014014891A (es) | 2012-06-05 | 2015-06-17 | Regeneron Pharma | Metodos para hacer anticuerpos biespecificos completamente humanos usando una cadena ligera comun. |
-
2011
- 2011-04-25 US US13/093,156 patent/US20120021409A1/en not_active Abandoned
-
2012
- 2012-04-24 RS RSP20191205 patent/RS59331B1/sr unknown
- 2012-04-24 KR KR1020137030963A patent/KR101995753B1/ko active Active
- 2012-04-24 SG SG2013076039A patent/SG194466A1/en unknown
- 2012-04-24 SI SI201230545T patent/SI2701499T2/sl unknown
- 2012-04-24 MX MX2013012500A patent/MX353609B/es active IP Right Grant
- 2012-04-24 ES ES12717033T patent/ES2573828T5/es active Active
- 2012-04-24 WO PCT/US2012/034737 patent/WO2012148873A2/en not_active Ceased
- 2012-04-24 DK DK12717033.0T patent/DK2701499T4/da active
- 2012-04-24 EP EP12717033.0A patent/EP2701499B2/en active Active
- 2012-04-24 SM SM20190514T patent/SMT201900514T1/it unknown
- 2012-04-24 HU HUE15186515A patent/HUE045401T2/hu unknown
- 2012-04-24 RU RU2013152221A patent/RU2614859C2/ru active
- 2012-04-24 DK DK15186515.1T patent/DK2989893T3/da active
- 2012-04-24 PT PT15186515T patent/PT2989893T/pt unknown
- 2012-04-24 PL PL15186515T patent/PL2989893T3/pl unknown
- 2012-04-24 EP EP15186515.1A patent/EP2989893B1/en active Active
- 2012-04-24 ES ES15186515T patent/ES2743681T3/es active Active
- 2012-04-24 LT LTEP15186515.1T patent/LT2989893T/lt unknown
- 2012-04-24 HU HUE12717033A patent/HUE027949T2/en unknown
- 2012-04-24 CN CN201510815765.5A patent/CN105884887A/zh active Pending
- 2012-04-24 JP JP2014508476A patent/JP6393613B2/ja active Active
- 2012-04-24 SI SI201231661T patent/SI2989893T1/sl unknown
- 2012-04-24 HR HRP20160484TT patent/HRP20160484T4/hr unknown
- 2012-04-24 AU AU2012249953A patent/AU2012249953B2/en active Active
- 2012-04-24 PL PL12717033T patent/PL2701499T5/pl unknown
- 2012-04-24 RU RU2017108634A patent/RU2017108634A/ru not_active Application Discontinuation
- 2012-04-24 RS RS20160309A patent/RS54831B2/sr unknown
- 2012-04-24 BR BR112013027420A patent/BR112013027420A2/pt not_active Application Discontinuation
- 2012-04-24 CA CA2846806A patent/CA2846806A1/en not_active Abandoned
- 2012-04-24 CN CN201280026269.6A patent/CN103596424B/zh active Active
-
2013
- 2013-10-17 IL IL228929A patent/IL228929A0/en unknown
-
2015
- 2015-04-06 US US14/679,949 patent/US20150313193A1/en not_active Abandoned
-
2016
- 2016-04-26 AU AU2016202609A patent/AU2016202609B2/en active Active
- 2016-05-09 SM SM201600133T patent/SMT201600133B/it unknown
- 2016-05-10 CY CY20161100398T patent/CY1117606T1/el unknown
- 2016-07-13 JP JP2016138445A patent/JP6522557B2/ja active Active
-
2018
- 2018-10-02 AU AU2018236913A patent/AU2018236913A1/en not_active Abandoned
-
2019
- 2019-09-17 HR HRP20191680 patent/HRP20191680T1/hr unknown
- 2019-09-17 CY CY20191100973T patent/CY1122036T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014516518A5 (enExample) | ||
| RU2017108634A (ru) | Отличные от человека животные, экспрессирующие антитела с общей легкой цепью | |
| JP2015509380A5 (enExample) | ||
| US12543713B2 (en) | Mice that make heavy chain antibodies | |
| JP2018138047A5 (enExample) | ||
| JP2015502177A5 (enExample) | ||
| JP2013532974A5 (enExample) | ||
| JP2015505477A5 (enExample) | ||
| JP2014524243A5 (enExample) | ||
| JP2013535213A5 (enExample) | ||
| JP2015525071A5 (enExample) | ||
| RU2014127339A (ru) | Мыши с гуманизированной легкой цепью | |
| JP2014529998A5 (enExample) | ||
| HRP20161551T4 (hr) | Miš sa zajedničkim lakim lancem | |
| JP2009524641A5 (enExample) | ||
| JP2014110814A5 (enExample) | ||
| RU2019121863A (ru) | Антитела со встроенным в легкие цепи гистидином и генетически модифицированные отличные от человека животные для их получения | |
| JP2015510769A5 (enExample) | ||
| RU2022109215A (ru) | Гуманизированные грызуны, которые экспрессируют тяжелые цепи, содержащие домены vl | |
| AU2014233618B2 (en) | Mice that make heavy chain antibodies | |
| HK40010699A (en) | Mice that make heavy chain antibodies | |
| RU2019115237A (ru) | Мыши, экспрессирующие ограниченный репертуар легких цепей иммуноглобулина | |
| NZ740900B2 (en) | Mice that make binding proteins comprising vl domains | |
| NZ740900A (en) | Mice that make binding proteins comprising vl domains |